A randomized, placebo-controlled, double-blind, repeat dose, dose escalation trial to investigate the safety, tolerability and pharmacokinetics of supratherapeutic doses of GSK189075 [remogliflozin etabonate] administered for 3 days in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 27 Aug 2007 Status change
- 13 Aug 2007 New trial record.